Two Hemophilia Drugs Lead Hematology Pipeline Update

Both drugs address an unmet need for patients with hemophilia A or B.

Patients with hemophilia and sickle cell both have unmet treatment needs, according toSandra Cuellar, a clinical associate professor and clinical oncology pharmacist at UI Health/University of Illinois at Chicago College of Pharmacy. During her Hematology/Oncology Pipeline Update presentation at the 2022 American Society of Health-System Pharmacists Summer Meetings and Exhibition,1 Cuellar dove into the drugs being researched for these conditions.

Check out our coverage of the 2022 ASHP Summer Meetings and Exhibition to learn more about the latest in the specialty drug pipeline.

Hematology Pipeline: Hemophilia and Sickle Cell Disease

Reference

  1. Cuellar S, Banks AM. Specialty pipeline updates I: hematology & oncology. Presented at: American Society of Health-System Pharmacists Summer Meetings & Exhibition; June 11-15, 2022; Phoenix, AZ